(Fianlimab)Biosimilar Reference Antibody-GS40265

货号：GS40265

Fianlimab (development code REGN-3767) is an investigational, fully human monoclonal antibody being developed for cancer immunotherapy. It functions as an antagonist of the Lymphocyte Activation Gene-3 (LAG-3) immune checkpoint. By binding with high affinity to LAG-3 on the surface of T cells and other immune cells, fianlimab blocks its interaction with major histocompatibility complex class II (MHC-II) molecules and other ligands. This blockade releases the inhibitory signal that LAG-3 imposes on T-cell activation, proliferation, and effector function, thereby aiming to restore anti-tumor immune responses, particularly in T cells that are exhausted or dysfunctional. Its development often focuses on combination therapy with other checkpoint inhibitors.